We are live on ! Find out more
ATHE icon

Alterity Therapeutics
ATHE

10 hedge funds and large institutions have $361K invested in Alterity Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more capital inflows, than outflows

Capital inflows: $62.2K | Capital outflows: $47.5K

25% more funds holding

Funds holding: 8 → 10 (+2)

0.69% more ownership

Funds ownership: 0% → 0.69% (+0.69%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Old Mission Capital
Old Mission Capital
Illinois
+$20.3K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$19.4K
3
Morgan Stanley
Morgan Stanley
New York
+$15K
4
UBS Group
UBS Group
Switzerland
+$6.81K
5
Wells Fargo
Wells Fargo
California
+$798

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$47.4K
2
AIM
Advantage Investment Management
Iowa
-$80
3
Advisor Group
Advisor Group
Arizona
-$16

ATHE Hedge Fund Activity: Q2 2019 in Review

10 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2019, worth a combined $361K — down 28% from $503K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ATHE positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Old Mission Capital, opening a new position worth an estimated $20.3K. The largest seller was Susquehanna International Group, cutting an estimated $47.4K.

  • 10 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2019, up from 8 in Q1 2019.
  • Funds reported $361K of Alterity Therapeutics stock for Q2 2019, down 28% quarter-over-quarter.
  • 3 funds opened new Alterity Therapeutics positions in Q2 2019 and 0 closed out, a net change of +3 holders.
  • The largest Alterity Therapeutics buyer in Q2 2019 was Old Mission Capital, an estimated $20.3K added.
  • The largest Alterity Therapeutics seller in Q2 2019 was Susquehanna International Group, an estimated $47.4K sold.

Based on aggregated 13F filings for Q2 2019.